Prior Auth Required

0343U - molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer

This procedure appears on the selected insurer prior authorization source.

Check another codeExplore policy data
Prior authorizationPrior Auth Required
Procedure / Servicemolecular evidence of no-, low-, intermediate- or high-risk of prostate cancer
Procedure / Service Description

Transcatheter renal sympathetic denervation, percutaneous approach including arterial - Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as 0343U molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum,

Likely documents
  • Confirm benefit details
  • Submit clinical notes if requested by the plan
Next actions
  • Confirm the current plan policy before submission.
  • Use the insurer authorization workflow for this listed code.